Roivant Sciences is a biopharmaceutical holding company that develops and commercializes medicines and health technologies through a network of subsidiary 'vant' companies.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Ancora | 42 | New buy | 25 | $914 | 0.0% |
| Steve Cohen / Point72 | 75 | Added +7% | 4,827,277 | $176,533,520 | 0.2% |
| David Einhorn / Greenlight | 45 | Trimmed -47% | 1,131,747 | $41,387,988 | 1.2% |
| Paul Tudor Jones / Tudor | 61 | Trimmed -45% | 52,200 | $1,908,954 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.